Epithelial ovarian cancer (EOC) is the most frequent cause of gynecologic malignancy-related mortality in women. Although advances in platinum/taxane-based chemotherapy have resulted in improved survival, patients typically experience disease relapse within 2 years of the initial treatment and develop resistance to therapy. Therefore, development of new therapies is a high priority. Molecular targeted drugs hold promise as independent therapeutic agents or chemotherapy response modifiers and could contribute substantial improvements to the outlook of women with EOC. microRNAs (miRNAs) are -22 nucleotide non-coding RNAs, which negatively regulate gene expression in a sequence-specific manner. We have generated the first evidence that miRNAs exhibit genomic alterations at high frequency and their expression is remarkably deregulated in ovarian cancer. This strongly suggests that miRNAs are involved in the initiation and progression of this disease. Indeed, our preliminary studies demonstrate that miRNA is a new class of novel biomarker with strong potential application to EOC in eariy detection, diagnosis and therapeutic response prediction. We hypothesize that miRNAs might serve two roles in the evolution of predictive and therapeutic strategies in EOC. First, it is possible that miRNAs might accurately predict response and resistance to a given chemotherapy. Second, and potentially more exciting in the long term, is the potential that selected mlRNA's might serve as therapeutic tools and/or chemotherapy response modifiers that will offer novel therapeutic opportunities for EOC. We propose the following specific aims to develop miRNA-based therapeutic tools for EOC.
Specific Aim 1 : Determine the function and therapeutic potential of select miRNAs in vitro.
Specific Aim 2 : Determine the therapeutic potential of select miRNAs in vivo.
Specific Aim 3 : Develop one or more constructs directed to specific mlRNA's in Phase l/ll trials.
Specific Aim 4 : Evaluate the predictive value of miRNAs response and resistance to a given chemotherapy.

Public Health Relevance

(See Instructions): Epithelial ovarian cancer is the most frequent cause of gynecologic cancer-related mortality in women. miRNAs are small non-coding RNAs, which negatively regulate gene expression in a sequence-specific manner. We will conduct a detailed study of miRNA in ovarian cancer, which has not been carried out to date, with the intent to (i) discover new biomarkers for ovarian cancer clinical management or prognosis;(ii) discover novel and important therapeutic targets.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083638-14
Application #
8380817
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
14
Fiscal Year
2012
Total Cost
$426,838
Indirect Cost
$101,693
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Yang, Lu; Zhang, Youyou; Shan, Weiwei et al. (2017) Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 9:
Beck, Tim N; Smith, Chad H; Flieder, Douglas B et al. (2017) Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. Head Neck 39:E34-E39
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Zhang, Dongmei; Zhang, Gao; Hu, Xiaowen et al. (2017) Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Res 77:3745-3757
Rebbeck, Timothy R; Friebel, Tara M; Mitra, Nandita et al. (2016) Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res 18:112
Zhong, Xiaomin; Zheng, Lan; Shen, Jianfeng et al. (2016) Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer. Mol Cell Biol 36:2742-2754
Beck, Tim N; Golemis, Erica A (2016) Genomic insights into head and neck cancer. Cancers Head Neck 1:
Zhang, Youyou; Feng, Yi; Hu, Zhongyi et al. (2016) Characterization of Long Noncoding RNA-Associated Proteins by RNA-Immunoprecipitation. Methods Mol Biol 1402:19-26
Prudnikova, T Y; Villamar-Cruz, O; Rawat, S J et al. (2016) Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells. Oncogene 35:2178-85
Beck, Tim N; Georgopoulos, Rachel; Shagisultanova, Elena I et al. (2016) EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Mol Cancer Ther 15:2486-2497

Showing the most recent 10 out of 317 publications